ABSTRACT
Abstract Herein we report a case of juvenile xantogranuloma, an inflammatory disease more commonly diagnosed during childhood and is characterized by cutaneous and ocular manifestations. Iris is the main target, presenting as local or diffuse yellowish lesions. Iris involvement may precipitate not only glaucoma but also amblyopia. Treatment is based on corticosteroids therapy, either local or systemic aiming disease control.
Resumo É relatado um caso raro de xantogranuloma juvenil, doença de natureza inflamatória diagnosticada mais frequentemente na infância, com manifestações cutâneas e oculares. A íris é o principal sítio extracutâneo da doença, apresentando-se como lesão amarelada, difusa ou localizada. O acometimento iriano pode acarretar surgimento de glaucoma, além de ambliopia. O manejo clínico da lesão ocular no presente caso foi baseado no necessidade no uso contínuo de corticoide tópico e sistêmico para estabilização da doença.
Subject(s)
Humans , Female , Infant , Xanthogranuloma, Juvenile/complications , Iris Diseases/etiology , Iris Diseases/drug therapy , Iris Diseases/diagnostic imaging , Ophthalmoscopy , Scalp/pathology , Scalp Dermatoses/etiology , Dexamethasone/administration & dosage , Hyphema , Prednisolone/administration & dosage , Glaucoma , Ultrasonography , Facial Dermatoses/etiology , Slit Lamp Microscopy , Fundus OculiABSTRACT
To describe three cases of neovascular glaucoma (NVG) where iris or angle neovascularization regressed remarkably after subconjunctival bevacizumab injections used as the initial treatment before pan retinal photocoagulation (PRP) and/or filtering surgery. Three consecutive NVG patients whose intraocular pressure (IOP) was not controlled with maximal medication were offered an off-label subconjunctival injection of bevacizumab (2.5-3.75 mg/0.1-0.15 mL, Avastin). Bevacizumab was injected into the subconjunctival space close to the corneal limbus in two or three quadrants using a 26-gauge needle. Serial anterior segment photographs were taken before and after the injection. Following subconjunctival injection of bevacizumab, iris or angle neovascularization regressed rapidly within several days. Such regression was accompanied by lowering of IOP in all three cases. The patients underwent subsequent PRP and/or filtering surgery, and the IOP was further stabilized. Our cases demonstrate that subconjunctival bevacizumab injection can be potentially useful as an initial treatment in NVG patients before laser or surgical treatment.
Subject(s)
Adult , Humans , Male , Middle Aged , Angiogenesis Inhibitors/administration & dosage , Antibodies, Monoclonal, Humanized/administration & dosage , Conjunctiva , Glaucoma, Neovascular/drug therapy , Injections, Intraocular , Iris Diseases/drug therapy , Treatment OutcomeABSTRACT
Describir el comportamiento de la rubeosis del iris luego de la aplicación de triamcinolona subtenoniana. Se realizó un estudio descriptivo de corte longitudinal con 25 pacientes para un total de 32 ojos con diferentes afecciones oculares. Se efectuaron pruebas estadísticas con las variables del estudio y en algunas se utilizó la prueba de los signos de comparación para datos pareados y en otras se aplicó chi cuadrado. Se caracterizaron las variables: edad, sexo, causa de rubeosis del iris y sus estadios, síntomas y tratamiento con láser de panfotocoagulación retiniana. La retinopatía diabética proliferativa fue la afección más frecuente en el 76 por ciento de los pacientes, seguida de la oclusión de la vena central retiniana. Del total de pacientes tratados, el 37,5 por ciento evolucionó satisfactoriamente el estado de la rubeosis del iris. Fue mayor el número de pacientes que mejoraron el grado de la rubeosis con tratamiento combinado de láser y triamcinolona subtenoniana, aunque estadísticamente no fue significativo. El estado de la rubeosis mejoró en más de la mitad de los pacientes con tiempo de evolución menor de 6 meses. En aquellos con un tiempo mayor de 6 meses y neovascularización del iris grado III, se pudo estabilizar el glaucoma neovascular. Se plantea que la triamcinolona subtenoniana constituye una alternativa para el manejo de este tipo de pacientes.
To describe the behaviour of iris rubeosis after using intravitreal triamcinolone. A longitudinal descriptive study was performed on 25 patients for a total number of 32 eyes with several ocular diseases. Statistical tests were made with the study variables; sign comparison for paired data and Chi square tests were applied. The variables were age, sex, cause of iris rubeosis and its staging, symptoms and treatment with retinal photocoagulation laser. Proliferative diabetic retinopathy was the most common disease in 76 percent of patients, followed by central retinal vein occlusion. Of the total number of treated patients, 37,5 percent had satisfactory recovery in terms of the iris rubeosis condition. The number of patients that improved rubeosis condition after a combined therapy of laser and intravitreal triamcinolone was higher but not statistically significant. Rubeosis condition improved in over 50 percent of patients whose rubeosis had developed in less than six months. However, in those patients with the disease affecting them for more than 6 months and third grade iris neovascularization, neovascular glaucoma could be stabilized. Intravitreal triamcinolone is an alternative for the management of this type of patients.
Subject(s)
Humans , Iris Diseases/drug therapy , Glaucoma, Neovascular/pathology , Intraocular Pressure , Diabetic Retinopathy/drug therapy , Triamcinolone/therapeutic useABSTRACT
Atrofia Essencial da Iris, Síndrome de Chandler e Síndrome de Coogan-Reese säo, atualmente, consideradas variaçöes de uma mesma patologia: Síndrome %) e seu controle é defícil. Portanto, o tratamento visa o controle da PIO e a manutençäo de uma boa acuidade visual. Os autores apresentam um caso de Síndrome de Coogan-Reese em uma paciente de 27 anos onde conseguiram restabelecer uma boa visäo através de uma pupiloplastia com Nd Yag Laser e o controle da PIO foi alcançado através do Implante de Molteno